David Shaw’s Pacira BioSciences PCRX Stock Holding History

David Shaw’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,600	Closed	-$256K	–	3720
2017 Q4	$256K	Buy	+5,600	New	+$222K	﹤0.01%	3315
2015 Q1	–	Sell	-10,000	Closed	-$887K	–	3905
2014 Q4	$887K	Sell	10,000 -2,500	-20%	-$236K	﹤0.01%	2915
2014 Q3	$1.21M	Buy	12,500 +10,000	+400%	+$973K	﹤0.01%	2647
2014 Q2	$230K	Sell	2,500 -11,300	-82%	-$860K	﹤0.01%	3932
2014 Q1	$966K	Hold	13,800	–	–	﹤0.01%	3053
2013 Q4	$793K	Buy	+13,800	New	+$726K	﹤0.01%	3367

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

David Shaw's PCRX Position: Q2 2026 in Review

David Shaw reduced its Pacira BioSciences (PCRX) stake by 1.6% in Q2 2026, selling an estimated $766K and leaving 1,950,332 shares worth $49.5M. The position accounts for 0.02% of the portfolio, ranked #766.

David Shaw first reported a position in PCRX in Q2 2013 and has held it in 41 quarters since. The position peaked at $56.3M in Q1 2025. 251 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

David Shaw held 1,950,332 shares of Pacira BioSciences worth $49.5M as of Q2 2026.
David Shaw sold 32,392 Pacira BioSciences shares in Q2 2026, an estimated $766K.
Pacira BioSciences made up 0.02% of David Shaw's portfolio in Q2 2026, its #766 holding.
David Shaw first reported a position in Pacira BioSciences in Q2 2013 and has held it in 41 quarters since.
David Shaw's Pacira BioSciences position peaked at $56.3M in Q1 2025.
251 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.